Q-omics provides the consensus-scored SYT11 profile across patient tissues and cancer cell-line models. SYT11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYT11 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SYT11 RNA expression shows 20,431 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where SYT11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT11 survival associations across molecular data types. SYT11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT11 RNA expression–survival associations across cancer types. High SYT11 expression shows unfavorable associations in MESO, UVM and BLCA, but favorable associations in KIRC, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYT11 RNA expression.
This table summarizes SYT11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SYT11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT11 shows lower tumor expression in KICH, LUSC, BLCA and LUAD and higher tumor expression in HNSC and LIHC. The KICH box plot shows higher SYT11 RNA expression in normal versus tumor tissue (log2 FC = −2.760, t-test p < 0.001).
This table shows molecular features associated with SYT11 in patient tissues and cancer cell lines. In patient samples, SYT11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
